Transcutaneous application of carbon dioxide (CO 2) enhances chemosensitivity by reducing hypoxic conditions in human malignant fibrous histiocytoma--174-181

Journal of Cancer Science and Therapy

Volumn 4, Issue 7, 2012, Pages 3-

  Onishi, Yasuo ^a   Kawamoto, Teruya ^a   Ueha, Takeshi ^b   Hara, Hitomi ^a   Fukase, Naomasa ^a   Toda, Mitsunori ^a   Harada, Risa ^a   Sakai, Yoshitada ^a   Miwa, Masahiko ^a   Nishida, Kotaro ^a   Kuroda, Ryosuke ^a   Kurosaka, Masahiro ^a   Akisue, Toshihiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NeoChemir Inc   (Japan)

Author keywords

Carbon dioxide (CO 2); Chemosensitivity; Hypoxia; HIF 1a; Malignant fibrous histiocytoma (MFH); Transcutaneous application

Indexed keywords

CARBON DIOXIDE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFICACY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TISSUE OXYGENATION; TRANSCRIPTION REGULATION; TRANSCUTANEOUS CARBON DIOXIDE APPLICATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR RESISTANCE;

EID: 84866107070     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000136     Document Type: Article

References (39)

1. Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, et al. (1996) Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer 77: 1823-1830.
2. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, et al. (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13: 1537-1545.
3. Verweij J, Pinedo HM (1991) Systemic treatment of advanced or metastatic soft tissue sarcomas. Cancer Treat Res 56: 75-91.
4. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, et al. (2000) Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18: 2676-2684.
5. Bussink J, Kaanders JH, van der Kogel AJ (2003) Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67: 3-15.
6. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, et al. (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941-943.
7. Smith E, Stratford IJ, Adams GE (1980) Cytotoxicity of adriamycin on aerobic and hypoxic chinese hamster V79 cells in vitro. Br J Cancer 42: 568-573.
8. Roizin-Towle L, Hall EJ (1978) Studies with bleomycin and misonidazole on aerated and hypoxic cells. Br J Cancer 37: 254-260.
9. Smith E, Stratford IJ, Adams GE (1979) Resistance of Hypoxic Mammalian-Cells to Chemotherapeutic-Agents. Brit J Cancer 40: 316.
10. Fedele AO, Whitelaw ML, Peet DJ (2002) Regulation of gene expression by the hypoxia-inducible factors. Mol Interv 2: 229-243.
11. Semenza GL (2007) Life with oxygen. Science 318: 62-64.
12. Fulda S, Debatin KM (2007) HIF-1-regulated glucose metabolism: a key to apoptosis resistance? Cell Cycle 6: 790-792.
13. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, et al. (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537.
14. Williams KJ, Telfer BA, Xenaki D, Sheridan MR, Desbaillets I, et al. (2005) Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 75: 89-98.
15. Song X, Liu X, Chi W, Liu Y, Wei L, et al. (2006) Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58: 776-784.
16. Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM, et al. (2007) Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol 37: 127-134.
17. Koga K, Nabeshima K, Nishimura N, Shishime M, Nakayama J, et al. (2005) Microvessel density and HIF-1alpha expression correlate with malignant potential in fibrohistiocytic tumors. Eur J Dermatol 15: 465-469.
18. Vaupel P (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14: 198-206.
19. Kaanders JH, Bussink J, van der Kogel AJ (2004) Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol 14: 233-240.
20. Resch KL, Just U (1994) Possibilities and limits of CO2 balneotherapy. Wien Med Wochenschr 144: 45-50.
21. Hartmann BR, Bassenge E, Pittler M (1997) Effect of carbon dioxide-enriched water and fresh water on the cutaneous microcirculation and oxygen tension in the skin of the foot. Angiology 48: 337-343.
22. Riggs A (1960) The Nature and Significance of the Bohr Effect in Mammalian Hemoglobins. J Gen Physiol 43: 737-752.
23. Sakai Y, Miwa M, Oe K, Ueha T, Koh A, et al. (2011) A novel system for transcutaneous application of carbon dioxide causing an "artificial Bohr effect" in the human body. PLoS One 6: e24137.
24. 2) on skeletal muscle. Biochem Biophys Res Commun 407: 148-152.
25. Onishi Y, Kawamoto T, Ueha T, Akisue T, Kishimoto K, et al. (2011) Mitochondrial proliferation induces apoptosis in human MFH cells by PGC-1α overexpression. ECCO 16: 310.
26. Kiyozuka Y, Nakagawa H, Uemura Y, Senzaki H, Yamamoto A, et al. (2001) Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. Cancer Genet Cytogenet 127: 7-15.
27. Okada Y, Akisue T, Hara H, Kishimoto K, Kawamoto T, et al. (2010) The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model. Anticancer Res 30: 3391-3395.
28. Takayama K, Ishida K, Matsushita T, Fujita N, Hayashi S, et al. (2009) SIRT1 regulation of apoptosis of human chondrocytes. Arthritis Rheum 60: 2731-2740.
29. Reinecke P, Steckstor M, Schmitz M, Gabbert HE, Gerharz CD (2004) Chemotherapeutic potential of plant alkaloids and multidrug resistance mechanisms in malignant fibrous histiocytoma of the heart. Oncol Rep 11: 641-645.
30. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741.
31. Demetri GD, Elias AD (1995) Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 9: 765-785.
32. Zucchi R, Danesi R (2003) Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anticancer Agents 3: 151-171.
33. Teicher BA (1995) Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am 9: 475-506.
34. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, et al. (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394.
35. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
36. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613.
37. Epstein RJ (2007) VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 26: 443-452.
38. Teicher BA (1994) Combination of perfluorochemical emulsions and carbogen breathing with cancer chemotherapy. Artif Cells Blood Substit Immobil Biotechnol 22: 1109-1120.
39. Kawasoe Y, Yokouchi M, Ueno Y, Iwaya H, Yoshida H, et al. (2009) Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of osteosarcoma. Oncol Rep 22: 1045-1050.